Form 4: Intra-Cellular Therapies Executive Sanjeev Narula Disposes of Shares in Johnson & Johnson Merger

Executive Vice President & CFO of Intra-Cellular Therapies, Sanjeev Narula, reports the disposal of stock options and restricted stock units due to the merger with Johnson & Johnson, where each share was converted into $132.00 in cash.

Summary

• Sanjeev Narula, Executive Vice President & CFO of Intra-Cellular Therapies, Inc. (ITCI), filed a Form 4 detailing changes in beneficial ownership.
• The filing is related to the merger between Intra-Cellular Therapies and Johnson & Johnson, which became effective on April 2, 2025.
• As a result of the merger, Intra-Cellular Therapies became a wholly-owned subsidiary of Johnson & Johnson.
• Each share of Intra-Cellular Therapies common stock was converted into the right to receive $132.00 in cash.
• Narula disposed of 17,251 stock options with an exercise price of $74.90.
• These options were converted into the right to receive cash equal to the difference between $132.00 and the exercise price, multiplied by the number of shares.
• Narula also disposed of 35,046 and 22,727 restricted stock units (RSUs), which were converted into the right to receive $132.00 per unit.
• For RSUs granted in 2025, the merger consideration will be payable at the time the original RSU would have vested, subject to accelerated vesting in certain circumstances.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The merger provides a clear cash value for shareholders and executives, indicating a successful outcome for Intra-Cellular Therapies.

Positives

• The merger provides a clear cash value of $132.00 per share for Intra-Cellular Therapies shareholders.
• Executive officers like Sanjeev Narula receive cash for their stock options and RSUs, reflecting the value created by the company.
• The accelerated vesting of RSUs in certain circumstances provides additional benefit to employees.

Future Outlook

The document does not contain specific forward-looking statements beyond the completion of the merger.

Industry Context

This announcement reflects ongoing consolidation within the pharmaceutical industry, with larger companies acquiring smaller, innovative firms to expand their product pipelines and market reach. Johnson & Johnson's acquisition of Intra-Cellular Therapies is consistent with this trend.

Comparison to Industry Standards

• Merger and acquisition (M&A) transactions in the pharmaceutical industry often involve a premium paid to the target company's shareholders.
• The $132.00 per share consideration suggests a premium was likely offered to Intra-Cellular Therapies shareholders.
• Comparable transactions include Pfizer's acquisition of Array BioPharma and AbbVie's acquisition of Allergan, both of which involved significant premiums.
• The valuation metrics in those deals, such as price-to-sales or price-to-earnings, could be compared to the implied valuation of Intra-Cellular Therapies in this merger.

Stakeholder Impact

• Shareholders receive $132.00 per share in cash.
• Employees with stock options and RSUs receive cash payments.
• The company becomes a wholly-owned subsidiary of Johnson & Johnson, potentially impacting future operations and strategy.

Key Dates

Keywords

Merger, Intra-Cellular Therapies, Johnson & Johnson, Sanjeev Narula, Stock Options, Restricted Stock Units, Form 4, Beneficial Ownership, ITCI